Dr. Anastasis Stephanou

School : The School of Medicine
Position : Professor, Molecular & Cellular Biology

Dr. Anastasis Stephanou Mailing Address
Nicosia
Cyprus

22559412 22559412

Email: A.Stephanou@euc.ac.cy A.Stephanou@euc.ac.cy

Profile

Dr Stephanou is a Reader/Associate Professor at University College London (UCL) and leads a group in the Medical Molecular Biology Unit. He completed his PhD at the Westminster and Charing Cross Medical School, University of London in 1992. He then did his Post-doctoral training (1992-1995) in the Department of Endocrinology, Cincinnati Children's Hospital, USA, working on transcriptional gene regulation. In 1995, he moved as a postdoctoral fellow to the Windeyer Institute of Medical Sciences, UCL where he studied the regulation of heat shock proteins and their cytoprotective properties. During his postdoctoral work, he developed his interest in the Signal Transducers and Activators of Transcription (STATs) factors as key regulators of apoptosis. In 2002, Dr Stephanou became a Lecturer at UCL and in 2005 was promoted to a Reader/Associate Professor. His main research interests is in the field of signal transduction in pathways and mechanisms of cell death (apoptosis), cell cycle regulation and autophagy in disease models such as myocardial infarction injury and also in cancer. Other interests include the use of primary cardiac, cardiac fibroblasts and endothelial cells in creating a beating cardiac tissue graft  to use in protocols for transplantation and treatment of severe heart failure models. He has recently edited a book entitled "JAK-STAT Pathway in Diseases" and also in 2012 became Editor-In-Chief of the journal JAK-STAT. He is an author for over 150 peer-reviewed articles.

 

Degrees

  • 1981 - 1985  University of East London, BSc  2:1 (Immunology)
  • 1988 - 1990  Birkbeck College  (London), MSc (Molecular Biology)
  • 1989 - 1992  Charing Cross & Westminster Med Sch, PhD (Molecular Endocrinology)

Publications

(0ver 150 including from 2009)

  • Scarabelli TM, Mariotto S, Abdel-Azeim S, Shoji K, Darra E, Stephanou A, Chen-Scarabelli C, Marechal JD, Knight R, Ciampa A, Saravolatz L, de Prati AC, Yuan Z, Cavalieri E, Menegazzi M, Latchman D, Pizza C, Perahia D, Suzuki H. (2009) Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury. FEBS Lett. 583:531-541.
  • Barry SP, Townsend PA, McCormick J, Knight RA, Scarabelli TM, Latchman DS, Stephanou A. (2009). STAT3 deletion sensitizes cells to oxidative stress. Biochem Biophys Res Commun. 385:324-329.
  • Ripley BJ, Fujimoto M, Serada S, Ohkawara T, Nishikawa T, Terabe F, Matsukawa Y, Stephanou A, Knight RA, Isenberg DA, Latchman DS, Kishimoto T, Naka T. (2010) Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. Int Immunol. 22: 359-366.
  • Bailey SG, Sanchez-Elsner T, Stephanou A, Cragg MS, Townsend PA. (2010) Regulating the genome surveillance system: miRNAs and the p53 super family. Apoptosis 15:541-552.
  • Yuan Z, McCauley R, Chen-Scarabelli C, Abounit K, Stephanou A, Knight R, Saravolatz SF, Saravolatz LD, Ulgen BO, Scarabelli GM, Faggian G, Mazzucco A, Saravolatz L, Scarabelli TM, Barry S. (2010) Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection. Mol Cell Endocrinol.  45:69-85.
  • Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS, Stephanou A. (2010) STAT3 modulates the DNA damage response pathway. Int J Exp Pathol. 91(6):506-514.
  • Carroll CJ, Suleman N, Davidson SM, Faulkes DJ, Diss JK, Knight R, Stephanou A, Latchman DS, Townsend PA. (2011) Transgenic overexpression of HSP56 does not result in cardiac hypertrophy nor protect from ischaemia/reperfusion injury. Int J Biochem Cell Biol. 43:74-79.
  • Barry SP, Lawrence KM, McCormick J, Soond SM, Hubank M, Eaton S, Sivarajah A, Scarabelli TM, Knight RA, Thiemermann C, Latchman DS, Townsend PA, Stephanou A. (2010) New targets of urocortin-mediated cardioprotection. J Mol Endocrinol. 45:69-85
  • Dimco G, Knight RA, Latchman DS, Stephanou A.  (2010) STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. Cell Cycle. 9:4638-4649.
  • Ng KE, Joly P, Jayasinghe SN, Vernay B, Knight R, Barry SP, McComick J, Latchman D, Stephanou A. (2011) Bio-electrospraying primary cardiac cells: in vitro tissue creation and functional study. Biotechnol J. 6:86-95.
  • McCormick J, Suleman N, Scarabelli TM, Knight RA, Latchman DS, Stephanou A. STAT1 Deficiency in the Heart Protects against Myocardial Infarction by Enhancing Autophagy. J Cell Mol Med. 1582-4934.
  • Ulgen BO, Field MG, Qureshi W, Knight RA, Stephanou A, Latchman DS, Vasquez D, Barry SP, Saravolatz L 2nd, Scarabelli GM, Faggian G, Mazzucco A, Saravolatz L, Chen-Scarabelli C, Scarabelli TM. (2011) The role of minocycline in ischemia-reperfusion injury: a comprehensive review of an old drug with new implications. Recent Pat Cardiovasc Drug Discov. 6:123-32.
  • Barry SB, Ounzain S, McCormick J, Scarabelli TM, Chen-Scarabelli C, Saravolatz L, Faggian G,Mazzucco A, Suzuki H, Thiemermann C, Knight RA, Latchman DS, and  Stephanou A. (2011) Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Intl J Cardiol. 163(3):326-34
  • McCormick J, Knight RA, Barry SP, Scarabelli TM, Abounit K, Latchman DS, Stephanou A. Autophagy in the stress-induced myocardium. (2012)  Front Biosci  2131 -2141.
  • Stephanou A. The beginning of the STAT: Letter from the Edito (2012)r. JAK-STAT 1;1(1):1.
  • Knight RA, Scarabelli TM, Stephanou A. STAT transcription in the ischemic heart.  JAKSTAT. 2012 1(2):111-117.
  • Carroll CJ, Sayan BS, Bailey SG, McCormick J, Stephanou A, Latchman DS, Townsend PA (2013(. J Interferon Cytokine Res. 33(9):542-8
  • Onorati F, Chen-Scarabelli C, Knight R, Stephanou A, Mohanti B, Santini F, Tessari M, Kini A, Narula J, Saravolatz L, Mazzucco A, Scarabelli T, Faggian G. (20 13) Targeting urocortin signaling pathways to enhance cardioprotection: is it time to move from bench to bedside?Cardiovasc Drugs Ther. 27(5):451-63.
  • Chen-Scarabelli C, Saravolatz Ii L, McCaukey R, Scarabelli G, Di Rezze J, Mohanty B, Barry S, Latchman D, Georgiadis V, McCormick J, Saravolatz L, Knight R, Faggian G, Narula J, Stephanou A, Scarabelli TM. The cardioprotective effects of urocortin are mediated via activation of the Src tyrosine kinase-STAT3 pathway.   (2013) JAKSTAT l 1;2(3):e24812
  • Bourke LT, Knight RA, Latchman DS, Stephanou A, McCormick J. (2013)  Signal transducer and activator of transcription-1 localizes to the mitochondria and modulates mitophagy. JAKSTAT 1;2(4):
  • Georgiadis V, Knight RA, Jayasinghe SN, Stephanou A.  (2014) Cardiac tissue engineering: renewing the arsenal for the battle against heart disease.  Integr Biol 6(2):111-26
  • Bourke L, McCormick J, Taylor V, Pericleous C, Blanchet B, Costedoat-Chalumeau N, Stuckey D, Lythgoe MF, Stephanou A, Ioannou Y. (2015) PLoS One.10(12):e0143771.
  • Bourke LT, McDonnell T, McCormick J, Pericleous C, Ripoll VM, Giles I, Rahman A, Stephanou A, Ioannou Y. Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. Cell Death Dis. 8(1):e2549.
  • Stephanou A, Patrikios I. (2017) 4th International Multithematic Scientific Bio-Medical Congress, Cyprus 2016. Cell Death Dis.  16;8(3):e2673.